Novel Oncolytic Chimeric Orthopoxvirus Causes Regression of Pancreatic Cancer Xenografts and Exhibits Abscopal Effect at a Single Low Dose

Newsfeed Image, Light Gray Text On Dark Gray Background
Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes the generation and characterization of a novel oncolytic chimeric orthopoxvirus for the treatment of pancreatic cancer.
Read more . . .